Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of GR1802 injection in moderate-to-severe asthma
CTR20221056Phase 2Completed
- Sponsor
- Zhixiang Jintai
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telikibart in asthma, sponsored by Zhixiang Jintai. Started Jul 2022; status: completed.
02
Drugs
telikibart
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20221056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221056.